• A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
    This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (90Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT).

  • In vitro and in vivo imaging and tracking of intestinal organoids from human-induced pluripotent stem cells
    Human intestinal organoids (hIOs) derived from human pluripotent stem cells (hPSCs) have immense potential as a source of intestines.

  • Global CAR T Cell Therapy Market to Reach US$ 8.5 Billion by 2028
    The Global Car T Cell Therapy Market is expected to be valued at US$ 8.5 Billion by 2028, as analyzed by Coherent Market Insights. Increasing demand for genetically engineered treatment approach for high success rate in cancer treatment along with growing cancer incidence rate are key factors driving demand for CAR T cell therapy products worldwide.

  • Engineered T cells for all
    Gene-engineered autologous T cells with chimeric antigen receptors (CARs) against CD19 (CART19 cells) have been effective against patients with CD19+ B cell malignancies.

  • UCLA Launches First-of-Its-Kind Stem Cell Trial to Combat Cancer
    Scientists at UCLA have launched the first genetically engineered blood stem cell clinical trial to fight cancer thanks to $20 million in voter-approved funds earmarked for stem cell research, university officials announced Monday.